Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

MOG peptide (35-55), mouse, rat acetate (Alias: Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, r...)

Catalog No. T7657L Copy Product Info
Purity: 97.88%
🥰Excellent
MOG peptide (35-55), mouse, rat acetate, is a minor component of central nervous system myelin with encephalitogenic activity. It can induce CD4⁺ T cell proliferation and Th1-type immune responses, leading to relapsing-remitting demyelinating disease. It is commonly used to establish experimental autoimmune encephalomyelitis (EAE) models.

MOG peptide (35-55), mouse, rat acetate

Copy Product Info
🥰Excellent
Catalog No. T7657L
Alias Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate, MOG peptide (35-55) , mouse, rat acetate (149635-73-4 Free base)

MOG peptide (35-55), mouse, rat acetate, is a minor component of central nervous system myelin with encephalitogenic activity. It can induce CD4⁺ T cell proliferation and Th1-type immune responses, leading to relapsing-remitting demyelinating disease. It is commonly used to establish experimental autoimmune encephalomyelitis (EAE) models.

MOG peptide (35-55), mouse, rat acetate
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$135In StockIn Stock
5 mg$393In StockIn Stock
10 mg$586In StockIn Stock
25 mg$939In StockIn Stock
50 mg$1,270In StockIn Stock
100 mg$1,720-In Stock
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:97.88%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
MOG peptide (35-55), mouse, rat acetate, is a minor component of central nervous system myelin with encephalitogenic activity. It can induce CD4⁺ T cell proliferation and Th1-type immune responses, leading to relapsing-remitting demyelinating disease. It is commonly used to establish experimental autoimmune encephalomyelitis (EAE) models.
In vitro
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) at concentrations ranging from 0 to 50 μg/mL for 72 hours induces T cell proliferation and triggers the secretion of Th1 cytokines, including TNF-α, IL-10, IFN-γ, IL-4, and IL-5. Moreover, it also enhances the production of IgG.[1]
In vivo
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55) (200 μg (0.2 mL); i.p.; once, for 38 d) demonstrates encephalitogenic properties in HLA-DR2 (DRB1*1501) mice[1].
Disease Modeling Protocol
Experimental autoimmune encephalomyelitis (EAE) model
  • Modeling Mechanism:

    MOG peptide (35-55), mouse and rat acetate can activate CD4⁺ T cells (Th1 and Th17 subsets), inducing CNS inflammatory infiltration, demyelination, and neurological dysfunction (in WT mice, T cell-mediated infiltration is predominant). GILT⁻/⁻ mice, due to antigen processing defects, cannot process MOG protein into MOG₃₅₋₅₅ epitopes, leading to a shift in the pathogenic mechanism to antibody-mediated infiltration—the production of pathogenic antibodies that recognize naturally glycosylated MOGs, which bind to MOGs on the surface of oligodendrocytes (OLs), inducing changes in cell morphology and functional disorders, while CNS infiltration is predominantly plasma cell-mediated.

  • Related Products:

    MOG peptide (35-55), mouse, rat acetate (T7657L)

  • Modeling Method:

    Experimental Subject:

    Mice: C57BL/6 (WT), GILT⁻/⁻ (C57BL/6 background); female; 6–10 weeks of age

    Dosage and Administration Route:

    300 μg MOG₃₅₋₅₅ peptide or 100 μg recombinant rat MOG protein, emulsified with CFA containing 300 μg Mycobacterium tuberculosis, subcutaneous injection; 500 ng pertussis toxin, intraperitoneal injection

    Dosing Frequency and Duration Model:

    Immunised once on days 0 and 7 (antigen+CFA); once on days 0 and 2 (PTX)

  • Validation:

    WT mice showed significant immunopathogenesis with MOG₃₅₋₅₅ (highest score 3.25), while GILT⁻/⁻ mice with rratMOG showed even more severe immunopathogenesis (highest score 4.25); inflammatory infiltration was observed in the CNS tissues (predominantly monocytes in WT, and predominantly CD38⁺CD138⁺ plasma cells in GILT⁻/⁻); serum anti-MOG antibody titers in GILT⁻/⁻ mice were > 1:25600, indicating the possibility of passive transfer of EAE.

*Precautions: All mice were sacrificed 40 days after modeling.

*References:Bergman CM,et,al. A switch in pathogenic mechanism in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in IFN-γ-inducible lysosomal thiol reductase-free mice. J Immunol. 2012 Jun 15;188(12):6001-9.

SynonymsMyelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate, MOG peptide (35-55) , mouse, rat acetate (149635-73-4 Free base)
Chemical Properties
Relative Density.no data available
SequenceH-MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH
Sequence ShortMEVGWYRSPFSRVVHLYRNGK
Storage & Solubility Information
Storagestore at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: 90 mg/mL, Sonication is recommended.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy MOG peptide (35-55), mouse, rat acetate | purchase MOG peptide (35-55), mouse, rat acetate | MOG peptide (35-55), mouse, rat acetate cost | order MOG peptide (35-55), mouse, rat acetate | MOG peptide (35-55), mouse, rat acetate chemical structure | MOG peptide (35-55), mouse, rat acetate in vivo | MOG peptide (35-55), mouse, rat acetate in vitro